US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Bulletin from the Extraordinary General Meetings in InDex Pharmaceuticals Holding AB (publ) on June 10, 2024

June 10, 2024 - InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals" or the "Company") entered into a conditional agreement on May 20, 2024 to acquire all shares in Flerie Invest AB ("Flerie") (the "Transaction"). The completion of the Transaction was, among other things, conditional upon resolutions at extraordinary general meetings in the Company and that the Company receives approval for continued listing on Nasdaq First North Growth Market. Today, on June 10, 2024, the extraordinary general meetings have been held in the Company to, inter alia, resolve on the Transaction. The

InDex Pharmaceuticals has received a conditional approval for continued listing on Nasdaq First North Growth Market after the reverse merger of Flerie

June 7, 2024 - InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals" or the "Company") has today received a conditional approval from Nasdaq Stockholm ("Nasdaq") for continued listing of the Company's share on Nasdaq First North Growth Market. The Company has previously submitted an application for approval for continued listing as a part of the completion of the reverse merger of Flerie Invest AB.BackgroundOn May 20, 2024, InDex Pharmaceuticals entered into a conditional agreement to acquire all shares in Flerie Invest AB ("Flerie") (the “Transaction"). The Transaction

InDex Pharmaceuticals publishes NAV for Flerie as of May 31, 2024

June 4, 2024 - InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals" or the "Company") entered into a conditional agreement on May 20, 2024 to acquire all shares in Flerie Invest AB ("Flerie") (the "Transaction"). In the acquisition, Flerie is valued at approximately SEK 3,073 million, representing a discount of approx. 15.7 percent compared to the Net Asset Value (NAV) above as of May 31, 2024. The acquisition takes place through a non-cash issue of shares in InDex Pharmaceuticals, meaning that each share in Flerie will correspond to approx. 54 newly issued shares in InDex

InDex Pharmaceuticals publishes company description in connection with the reverse merger of Flerie

May 27, 2024 - InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals" or the "Company") entered into a conditional agreement on May 20, 2024 to acquire all shares in Flerie Invest AB ("Flerie") (the "Transaction"). The Company is today publishing a company description in connection with the Transaction (the "Company Description").BackgroundOn May 20, 2024, InDex Pharmaceuticals entered into an agreement to acquire all shares in Flerie through an issue in kind. The Transaction constitutes a so-called reverse merger whereby Flerie becomes a wholly owned subsidiary of InDex

Notice of extraordinary general meeting in InDex Pharmaceuticals Holding AB (publ)

May 23, 2024 - The shareholders of InDex Pharmaceuticals Holding AB , reg.no. 559067-6820 (the "Company" or "InDex Pharmaceuticals"), are hereby summoned to an extraordinary general meeting on Monday June 10, 2024 at 08.30 a.m. CEST at Setterwalls Advokatbyrå's premises at Sturegatan 10 in Stockholm.NoticeShareholders wishing to participate in the meeting must:  (i) be entered in the shareholders’ register, kept by Euroclear Sweden AB on the record day which is Thursday, May 30, 2024; and  (ii) no later than Monday, June 3, 2024, have notified the Company of their participation and

InDex Pharmaceuticals has entered into a conditional agreement regarding a reverse merger with Flerie

20 May 2024 – InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals" or the "Company") has today entered into a conditional agreement to acquire all shares in Flerie Invest AB. The acquisition is made through an issue in kind of 6,073,952,948 new shares in the Company, following which Flerie Invest AB's shareholders will initially hold approximately 91.9 per cent of the shares and InDex Pharmaceuticals' existing shareholders will initially hold approximately 8.1 per cent of the shares in the Company.The transaction in brief · InDex Pharmaceuticals has entered into an

Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)

May 7, 2024 – The annual general meeting in InDex Pharmaceuticals Holding AB (publ) was held on Tuesday 7 May 2024. The following resolutions, amongst others, were passed at the general meeting.Adoption of the profit and loss statements and balance sheets, disposal of profits, and resolution regarding discharge of liabilityThe annual general meeting resolved to adopt the profit and loss statement and balance sheet and the group’s profit and loss statement and balance sheet for the financial year of 2023. The annual general meeting resolved, in accordance with the board of directors’

InDex Pharmaceuticals provides a status update and informs about Extraordinary General Meeting on June 10, 2024

May 6, 2024 - InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals" or the "Company") announces that the evaluation of options for the future of the Company, including the reverse merger communicated in a press release on April 8, 2024 (the “Transaction”), is still ongoing. In a separate press release, the Board of Directors of InDex Pharmaceuticals convenes an Extraordinary General Meeting to be held on June 10, 2024.Following the discontinuation of the development of cobitolimod and the announcement that the Company will not continue the development of any of its other

Notice of extraordinary general meeting in InDex Pharmaceuticals Holding AB (publ)

May 6, 2024 - The shareholders of InDex Pharmaceuticals Holding AB, reg.no. 559067-6820 (the "Company"), are hereby summoned to an extraordinary general meeting on Monday, June 10, 2024, at 08.00 CEST at Setterwalls’ premises at Sturegatan 10 in Stockholm. Registration for the meeting starts at 07.30 CEST.NoticeShareholders wishing to participate in the meeting must:  (i) be entered in the shareholders’ register, kept by Euroclear Sweden AB (the Swedish Central Securities Depository & Clearing Organisation), on the record day which is Thursday, May 30, 2024; and  (ii) notify the

InDex Pharmaceuticals Holding AB (publ) interim report January – March 2024

InDex discontinues the development of cobitolimodPeriod January – March 2024 · Net sales amounted to SEK 10.8 (0.0) million · Operating loss amounted to SEK –5.3 (–44.3) million · Result after tax amounted to SEK –3.0 (–41.8) million, corresponding to SEK –0.01 per share (–0.08) before and after dilution · Cash flow from operating activities amounted to SEK –33.7 (–23.1) million · Cash and cash equivalents at the end of the period amounted to SEK 269.8 (319.4) million · Number of employees at the end of the period was 4 (5) · Number of shares at the end of the period

InDex Pharmaceuticals brings forward the publication of the interim report for Q1 2024

22 April, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) announces that the company changes the date for when the interim report for Q1 2024 will be published. The interim report will now be published on Friday April 26, 2024 instead of Tuesday May 7, 2024 as previously communicated.The reason for bringing forward the publication of the interim report is to facilitate and speed up the process of determining if the reverse merger being evaluated is achievable. For more information:Jenny Sundqvist, CEOPhone: +46 8 122 038 50E-mail: jenny.sundqvist@

InDex Pharmaceuticals provides a company update

8 April, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) announces that the evaluation of alternatives for the Company´s future, as communicated in a press release on February 26, 2024, has been finalized and presented to the Board according to plan.A step-wise approach was adopted to narrow down the number of options. The evaluation was conducted with support from an external financial advisor with the aim to maximize shareholder value. The Board has decided to proceed with the recommended reverse merger. Further steps are now being taken to ensure that the

InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2023

April 8, 2024 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2023. The Annual Report is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/financial-reports/.The Annual Report is mailed to shareholders and other stakeholders who specifically request it. Send request to info@indexpharma.com, or by mail to InDex Pharmaceuticals Holding AB (publ), Berzelius väg 13, 171 65 Solna, Sweden. For more information:Jenny Sundqvist, CEOPhone: +46 8 122 038 50E-mail: jenny.sundqvist@indexpharma.com Johan Giléus, CFO

Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)

N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the annual general meeting. In case of any discrepancies between the Swedish and English language versions, the Swedish version shall prevail April 5 2024 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820 (the “Company”), are hereby summoned to the Annual General Meeting on Tuesday May 7, 2024 at 17.00 (CET) at Setterwalls Advokatbyrå’s offices at Sturegatan 10 in Stockholm. Registration for the meeting commences at 16.30 (CET).NoticeShareholders wishing to

CEO and CFO both to leave InDex Pharmaceuticals

March 26, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) today announced that CEO Jenny Sundqvist and CFO & Deputy CEO Johan Giléus will leave the company per September 26, 2024.Jenny Sundqvist and Johan Giléus will both remain in their positions and at the company’s disposal until their last day of employment. "I would like to thank Jenny and Johan for their valuable contributions and for a very good collaboration. Unfortunately, our phase III study did not deliver as we had hoped for, and all current operations are being closed down. I wish both Jenny and

InDex Pharmaceuticals provides an update on company’s future

26 February, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) announces that, in light of today’s separate press release, with the announcement that the development of cobitolimod is discontinued, the company is evaluating other alternatives to maximize shareholder value. Alternatives such as merger and reverse merger are weighed against company liquidation. InDex Pharmaceuticals will not proceed with development of any of its other compounds.A step-wise approach has been adopted to narrow down the number of options. Company liquidation is considered in parallel at

InDex Pharmaceuticals discontinues the development of cobitolimod

26 February, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) today announced that the company will discontinue development of their drug candidate cobitolimod. Thorough analysis of the data from Induction Study 1 of the phase III program CONCLUDE has not provided any results justifying continued development.Induction Study 1 of the phase III program CONCLUDE, evaluating cobitolimod as a new treatment for moderate to severe left-sided ulcerative colitis, was discontinued on November 21, 2023 based on the advice from an independent Data Monitoring Committee (DMC). The

InDex Pharmaceuticals Holding AB (publ) year-end report 2023

Full focus on closing phase III programPeriod October – December 2023 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –107.9 (–58.2) million · Result after tax amounted to SEK –105.5 (–56.3) million, corresponding to SEK –0.20 per share (–0.11) before and after dilution · Cash flow from operating activities amounted to SEK –47.0 (–34.2) million Period January – December 2023 · Net sales amounted to SEK 97.5 (0.0) million · Operating result amounted to SEK –107.4 (–103.2) million · Result after tax amounted to SEK –95.3 (–100.3)

InDex Pharmaceuticals announces expected cash balance per March 31, 2024

19 January, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) today announced that remaining commitments for the company have been quantified, and the expected cash balance per March 31, 2024, amounts to SEK 180-190 million.The amount includes all closing costs for the phase III program CONCLUDE, even though activities for closing the phase III program will continue also after March 31, 2024. The company will have additional operating costs required to fulfill obligations of a listed company after March 31, 2024 amounting to SEK 0.6-0.8 million per month. InDex

InDex Pharmaceuticals Holding AB (publ) interim report January-September 2023

InDex Pharmaceuticals discontinues cobitolimod phase III program”This surprising and disappointing news confirms the complexity of the disease and the need for further research within this field, especially as moderate to severe ulcerative colitis is an indication with high unmet medical need for new treatment options. We are incredibly grateful to all the patients, investigators and study personnel for their engagement to date. We will conduct a comprehensive analysis of all the study data before announcing next steps,” said Jenny Sundqvist, CEO of InDex Pharmaceuticals. Period July –

InDex Pharmaceuticals discontinues cobitolimod phase III program

· Independent Data Monitoring Committee (DMC) advises that cobitolimod is unlikely to meet the primary endpoint upon completion of Induction Study 1 · More information regarding next steps will be provided once a thorough analysis of the data from Induction Study 1 has been completed 21 November, 2023 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) today announces that an independent DMC has completed the planned dose selection analysis including safety review and assessment for futility in Induction Study 1 of the phase III program CONCLUDE. The DMC advises that

InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2024 Annual General Meeting

October 30, 2023 – InDex Pharmaceuticals Holding AB (publ) today announced the composition of the Nomination Committee for the 2024 Annual General Meeting. The responsibility of the Nomination Committee is to present to the 2024 Annual General Meeting proposals regarding election of the Chairman of the Board and other members of the Board, fees and any other remuneration to the members of the Board as well as election and remuneration of the auditors.The Nomination Committee for the 2024 Annual General Meeting of InDex Pharmaceuticals Holding AB (publ) consists of: · Karl Tobieson,

InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea

October 20, 2023 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the Korean Intellectual Property Office. The patent provides protection for the use of cobitolimod in the treatment of inflammatory bowel disease.The patent (patent number: 10-2592716) will provide an exclusivity period until August 2040, with the possibility of up to 5 years patent term extension upon market approval. Corresponding patent applications have previously been granted in Europe and Hong Kong and filed in additional

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe